Pharmaceutical

AmyriAD leaves no leaf unturned with upcoming Phase III Alzheimer’s trials

The company aims to drive a small molecule resurgence with its lead Alzheimer’s symptom relief agent AD-101.

Jan 5, 2024 - 18:00
AmyriAD leaves no leaf unturned with upcoming Phase III Alzheimer’s trials
The company aims to drive a small molecule resurgence with its lead Alzheimer’s symptom relief agent AD-101.
Read the original article

Tags:

Previous Article

STAT+: Goldman Sachs launches $650 million fund for life sciences investments

Next Article

Signal: UK online pharmacies selling prescription drugs without proper checks

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Armed with Phase III win, Incyte eyes label expansion for Monjuvi

Armed with Phase III win, Incyte eyes label expansion f...

Aug 17, 2024

STAT+: Pharmalittle: White House drug-shortage task force brainstorms fixes; U.S. pharma layoffs are ballooning

STAT+: Pharmalittle: White House drug-shortage task for...

Aug 5, 2023

Magazine: UK’s new Netflix-style funding model for antibiotics goes live

Magazine: UK’s new Netflix-style funding model for anti...

Jun 26, 2024